Carrión R E, McLaughlin D, Auther A M, Olsen R, Correll C U, Cornblatt B A
Division of Psychiatry Research,The Zucker Hillside Hospital,North Shore - Long Island Jewish Health System (NS-LIJHS),Glen Oaks,NY,USA.
Psychol Med. 2015 Nov;45(15):3341-54. doi: 10.1017/S0033291715001233. Epub 2015 Jul 14.
Although cognitive deficits in patients with schizophrenia are rooted early in development, the impact of psychosis on the course of cognitive functioning remains unclear. In this study a nested case-control design was used to examine the relationship between emerging psychosis and the course of cognition in individuals ascertained as clinical high-risk (CHR) who developed psychosis during the study (CHR + T).
Fifteen CHR + T subjects were administered a neurocognitive battery at baseline and post-psychosis onset (8.04 months, s.d. = 10.26). CHR + T subjects were matched on a case-by-case basis on age, gender, and time to retest with a group of healthy comparison subjects (CNTL, n = 15) and two groups of CHR subjects that did not transition: (1) subjects matched on medication treatment (i.e. antipsychotics and antidepressants) at both baseline and retesting (Meds-matched CHR + NT, n = 15); (2) subjects unmedicated at both assessments (Meds-free CHR + NT, n = 15).
At baseline, CHR + T subjects showed large global neurocognitive and intellectual impairments, along with specific impairments in processing speed, verbal memory, sustained attention, and executive function. These impairments persisted after psychosis onset and did not further deteriorate. In contrast, CHR + NT subjects demonstrated stable mild to no impairments in neurocognitive and intellectual performance, independent of medication treatment.
Cognition appears to be impaired prior to the emergence of psychotic symptoms, with no further deterioration associated with the onset of psychosis. Cognitive deficits represent trait risk markers, as opposed to state markers of disease status and may therefore serve as possible predictors of schizophrenia prior to the onset of the full illness.
尽管精神分裂症患者的认知缺陷在发育早期就已存在,但精神病对认知功能进程的影响仍不明确。在本研究中,采用嵌套病例对照设计来检验在研究期间发展为精神病的临床高危(CHR)个体中,新发精神病与认知进程之间的关系(CHR + T)。
对15名CHR + T受试者在基线和精神病发作后(8.04个月,标准差 = 10.26)进行了神经认知测试。CHR + T受试者在年龄、性别和重新测试时间方面逐例与一组健康对照受试者(CNTL,n = 15)以及两组未发生转变的CHR受试者进行匹配:(1)在基线和重新测试时在药物治疗(即抗精神病药和抗抑郁药)方面匹配的受试者(药物匹配的CHR + NT,n = 15);(2)在两次评估时均未用药的受试者(无药的CHR + NT,n = 15)。
在基线时,CHR + T受试者表现出严重的整体神经认知和智力损害,以及在处理速度、言语记忆、持续注意力和执行功能方面的特定损害。这些损害在精神病发作后持续存在且未进一步恶化。相比之下,CHR + NT受试者在神经认知和智力表现方面表现出稳定的轻度至无损害,与药物治疗无关。
认知似乎在精神病症状出现之前就已受损,且与精神病发作无关的进一步恶化。认知缺陷代表特质风险标志物,而非疾病状态的状态标志物,因此可能在精神分裂症完全发病之前作为其可能的预测指标。